ASH 2022 | Using targeted therapies to optimize transplant outcomes in AML

Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil, University of Birmingham, Birmingham, UK, comments on the evolving role of allogeneic stem cell transplant (alloSCT) in acute myeloid leukemia (AML) in the age of targeted therapies. He explains that alloSCT remains a pivotal part of AML management, and that he foresees targeted therapies will be increasingly used to improve alloSCT outcomes and reduce its toxicity. Key areas of development include the use of FLT3 inhibition as maintenance to prevent relapse with agents such as sorafenib and gilteritinib, the use of BCL2 inhibitor venetoclax as a lower-intensity bridging therapy or as maintenance, and the use of targeted therapies to enhance graft-versus-leukemia (GvL) effect while limiting graft-versus-host disease (GvHD). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.